Evidence map›Paper›PMID 41204857›Full record

ArticleJournal of medical virology2025

Changes in HIV-1 Reservoir Dynamics After Mpox Infection.

Guiomar Casado-Fernández, Olivia de la Calle-Jiménez, Inés Armenteros, Luis Lemus Aguilar, Daniel Fuertes, Juan Cantón, Elena Mateos, Noemi Cabello, Javier Rodríguez Añover, Anabel Negredo and 5 more

Abstract read
In one paragraph

Article in Journal of medical virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Guiomar Casado-FernándezImmunopathology and Viral Reservoir Unit, National Center of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
Olivia de la Calle-JiménezImmunopathology and Viral Reservoir Unit, National Center of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.ORCID https://orcid.org/0009-0002-6962-1537
Inés ArmenterosInfectious Diseases Unit, Internal Medicine Service, Hospital Clínico San Carlos-IdISSC, Madrid, Spain.
Luis Lemus AguilarImmunopathology and Viral Reservoir Unit, National Center of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
Daniel FuertesSchool of Telecommunications Engineering, Universidad Politécnica de Madrid, Madrid, Spain.
Juan CantónInternal Medicine Service, Hospital Universitario de Móstoles, Madrid, Spain.
Elena MateosImmunopathology and Viral Reservoir Unit, National Center of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
Noemi CabelloInfectious Diseases Unit, Internal Medicine Service, Hospital Clínico San Carlos-IdISSC, Madrid, Spain.
Javier Rodríguez AñoverInfectious Diseases Unit, Internal Medicine Service, Hospital Clínico San Carlos-IdISSC, Madrid, Spain.
Anabel NegredoBiomedical Research Center Network in Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
Miguel CerveroSchool of Medicine, Universidad Alfonso X El Sabio, Madrid, Spain.
María Paz Sánchez SecoBiomedical Research Center Network in Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.ORCID https://orcid.org/0000-0001-9033-7704
Montserrat TorresImmunopathology and Viral Reservoir Unit, National Center of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
Vicente EstradaInfectious Diseases Unit, Internal Medicine Service, Hospital Clínico San Carlos-IdISSC, Madrid, Spain.
Mayte CoirasImmunopathology and Viral Reservoir Unit, National Center of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.ORCID https://orcid.org/0000-0001-6464-5770

Funding

Tyrosine Kinase inhibition: The New Front in HIV Cure EffortsR01AI143567 · NIAID · UNIVERSITY OF UTAH · PI COIRAS, MAYTE, PLANELLES, VICENTE · 2019 to 2023
$2.3M
NIAID NIH HHS R01 AI143567This study was supported by Centro de Investigación Biotecnológica en Red de Enfermedades Infecciosas, Ministerio de Ciencia, Innovación y Universidades and National Institutes of Health.
6 · The paper itself

Abstract

In May 2022, a large outbreak of monkeypox virus (MPXV) occurred in several non-endemic regions worldwide. Another outbreak in 2024 raised global concerns, particularly for immunocompromised individuals like people with HIV (PWH). Since the latent HIV-1 reservoir remains a major barrier to a cure, we investigated how past mpox infection affected reservoir dynamics in this population. PWH who had mpox at an average of 9 months before sampling showed a significantly smaller HIV-1 reservoir than MPXV-unexposed PWH. This reduction was accompanied by enhanced antigen-driven proviral reactivation in CD4+ T cells, especially central memory cells (TCM), and increased expression of T-cell activation and proliferation markers like CD32 and Ki67. Mpox also induced sustained immune stress, as reflected by a prolonged decrease in CD4+ T naïve (TN) cells, increased expression of immune senescence and exhaustion markers like PD-1, LAG-3, and CD57, as well as metabolic dysfunction in CD4+ TN and TCM cells, which showed impaired glucose uptake and reduced proliferative capacity. These findings suggest that MPXV-induced immune activation leads to long-lasting changes in T-cell homeostasis and reprograms the HIV-1 reservoir, which may have implications for monitoring immune competence and vaccine responses in this population. Understanding the interplay between HIV-1/MPXV co-infection, T-cell dynamics, and HIV-1 reservoir modulation provides novel insights into how controlled proviral reactivation may inform the design of cure-oriented strategies.

Indexed as

HIV-1HIV InfectionsMpox, MonkeypoxAdultCD4-Positive T-LymphocytesFemaleHumansLymphocyte ActivationMaleMiddle AgedViral LoadVirus ActivationVirus LatencyCD4+ coinfectionHIV‐1lymphocyte activationmpoxMPXVT cellsviral reservoir

Identifiers

PMID41204857
PMCPMC12595786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.